OABI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OABI News | Roxom Stocks

OA

Mkt Cap

$666.6M

Volume

897.75K

Next Earnings

October 30th

Loading chart

OA

OABIOmniAb, Inc. Common Stock

OABI

Pay with—

Available Balance0.00

OA

Mkt Cap

$667.3M

Volume

897.75K

Next Earnings

October 30th

Chart Financials Earnings News About Insider Filings

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to BuyOmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 shows no year-over-year change at -$0.35 per share, but analysts have raised estimates by 10.3% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.Zacks Investment Research · Oct 6, 2026

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.The Motley Fool · Aug 29, 2026

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development TimelinesVERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.GlobeNewswire Inc. · Jul 6, 2026

AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now UnderwayAI is transforming healthcare through innovative technologies like disease screening, genetic testing, antibody discovery, and drug development platforms, with several companies making significant technological advancements in medical AI applications.Benzinga · Jun 30, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramVERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.GlobeNewswire Inc. · May 5, 2025

USANA Health Sciences (USNA) Q1 Earnings and Revenues Top EstimatesUSANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Apr 30, 2024

Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are BuyingAlthough U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Hallador Energy The Trade: Hallador Energy Company (NASDAQ: HNRG) Director Charles Ray Wesley IVBenzinga · Mar 26, 2024

Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesPlus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Mar 5, 2024

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue EstimatesKaryopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Feb 29, 2024

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.Zacks Investment Research · Feb 28, 2024

to start trading

OA

OABIOmniAb, Inc. Common Stock

OABI

Pay with—

Available Balance0.00

Your PositionYou don't own any OABI yet.

Related Tickers

Earnings